Printer Friendly

Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2019.

ENPNewswire-September 5, 2019--Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2019

(C)2019 ENPublishing - http://www.enpublishing.co.uk

Release date- 04092019 - CRANBURY - Amicus Therapeutics (Nasdaq: FOLD) today announced upcoming presentations at the following investor conferences in September.

Bradley Campbell, President and Chief Operating Officer, and Jeff Castelli, Chief Portfolio Officer and Head of Gene Therapy, will participate in a fireside chat at the Baird 2019 Global Healthcare Conference in New York, NY on Thursday, September 5, 2019 at 9:40 a.m. ET.

Daphne Quimi, Chief Financial Officer, will present at the Janney Healthcare Conference in New York, NY on Tuesday, September 10, 2019 at 11:50 a.m. ET.

A live audio webcast of both presentations can be accessed via the Investors section of the Amicus Therapeutics corporate website at http://ir.amicusrx.com/events-and-presentations, and will be archived for 90 days.

About Amicus Therapeutics

Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases.

Contact:

Marco Winkler

Tel: (609) 662-2798

Email: mwinkler@amicusrx.com

[Editorial queries for this story should be sent to newswire@enpublishing.co.uk]

((Distributed via M2 Communications - http://www.m2.com))

COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:ENP Newswire
Date:Sep 5, 2019
Words:231
Previous Article:Anika Therapeutics to Host Analyst and Investor Day on September 18, 2019.
Next Article:Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4).

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |